Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland

Javier Perez-Saez¹,², Stephen A Lauer¹, Laurent Kaiser³,⁴,⁵, Simon Regard⁶,⁷, Elisabeth Delaporte⁷, Idris Guessous⁵,⁸, Silvia Stringhini⁵,⁸, Andrew S Azman¹,²,* for the Serocov-POP Study Group

1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA
2. Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland
3. Geneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Switzerland
4. Division of Laboratory Medicine, Geneva University Hospitals, Switzerland
5. Faculty of Medicine, University of Geneva, Switzerland
6. Department of Acute Medicine, Division of Emergency, Geneva University Hospitals, Switzerland
7. Cantonal Health Service, General Directorate for Health, Geneva, Switzerland
8. Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Switzerland

The infection fatality risk (IFR) is the average number of deaths per infection by a pathogen and is key to characterizing the severity of infection across the population and for specific demographic groups. To date, there are few empirical estimates of IFR published due to challenges in measuring infection rates.¹,² Outside of closed, closely surveilled populations where infection rates can be monitored through viral surveillance, we must rely on indirect measures of infection, like specific antibodies. Representative seroprevalence studies provide an important avenue for estimating the number of infections in a community, and when combined with death counts can lead to robust estimates of the IFR.

We estimated overall and age-specific IFR for the canton of Geneva, Switzerland using age-stratified daily case and death incidence reports combined with five weekly population-based seroprevalence estimates.³ From February 24th to June 2nd there were 5'039 confirmed cases and 286 reported deaths within Geneva (population of 506'765). We inferred age-stratified (5-9, 10-19, 20-49, 50-65 and 65+) IFRs by linking the observed number of deaths to the estimated number of infected individuals from each serosurvey. We account for the delays between infection and seroconversion as well as between infection and death.⁴ Inference is drawn in a Bayesian framework that incorporates uncertainty in seroprevalence estimates (supplement).

Of the 286 reported deaths caused by SARS-CoV-2, the youngest person to die was 31 years old. Infected individuals younger than 50 years experienced statistically similar IFRs (range 0.00032-0.0016%), which increases to 0.14% (95% CrI 0.096-0.19) for those 50-64 years old to 5.6% (95% CrI 4.3-7.4) for those 65 years and older (supplement). After accounting for demography and age-specific seroprevalence, we estimate a population-wide IFR of 0.64% (95% CrI 0.38-0.98).
Our results are subject to two notable limitations. Among the 65+ age group that died of COVID-19 within Geneva, 50% were reported among residents of assisted care facilities, where around 0.8% of the Geneva population resides. While the serosurvey protocol did not explicitly exclude these individuals, they are likely to have been under-represented. This would lead to an overestimation of the IFR in the 65+ age group if seroprevalence in this institutionalized population was higher than in the general population (supplement). Further, our IFR estimates are based on current evidence regarding post-infection antibody kinetics, which may differ between severe and mild infections. If mild infections have significantly lower and short-lived antibody responses, our estimates of IFR may be biased upwards.\(^5\)

Estimates of IFR are key for understanding the true pandemic burden and for weighing different risk reduction strategies. The IFR is not solely determined by host and pathogen biology, but also by the capacity of health systems to treat severe cases. Despite having among the highest per capita incidence in Switzerland, Geneva's health system accommodated the influx of cases needing intensive care (peak of 80/110 ICU-beds including surge capacity) while maintaining care quality standards. As such, our IFR estimates can be seen as a best-case scenario with respect to health system capacity. Our results reveal that population-wide estimates of IFR mask great heterogeneity by age and point towards the importance of age-targeted interventions to reduce exposures among those at highest risk of death.

References


2 Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates. DOI:10.1101/2020.05.03.20089854.


^SEROCoV-POP STUDY Group: Silvia Stringhini1, 2, 3, Idris Guessous1, 2, Andrew S. Azman4, 5, Hélène Bayssón2, Prune Collombet1, 2, David De Ridder2, Paola d’Ippolito1, Yaron Dibner1, Natalie Franciolli1, Kailing Marcus1, Chantal Martinez1, Natacha Noel1, Francesco Pennacchio1, Dusan Petrovic1, 3, Attilio Picazio1, Giovanni Piumatti1, 8, Jane Portier1, Caroline Pugin1, Barinjaka Rakotomiaramana1, Aude Richard1, 4, Stephanie Schrempfl1, Maria-Eugenia Zaballa1, Ania Wisniak4, Antoine Flahault1, 2, 4, Isabelle Arm Vernez9, Olivia Keiser4, Loa Mattera17, Magdalena Schellungova2, Laurent Kaiser2, 6, 9, 14, Isabella Eckerle2, 8, 9, Pierre Lescuyer6, Benjamin Meyer2, 13, Géraldine Poulain3, Nicolas Vuilleumier2, 6, Sabine Yerly6, 9, Sultan Bahta2, Jonathan Barbolini2, Rebecca Butzberger2, Sophie Cattani2, Alioucha Davidovic2, Antoine Daeniker2, Eugénie de Weck18, Céline Dubas2, Joséphine Duc2, Céline Eelbode2, Benoit Favre4, Alice Gilson2, Julie Guérin2, Lina Hassar2, Aurélie Hepner2, Francesca Hovagemyan2, Melis Kir2, Fanny Lombard2, Amélie Mach2, Eva Marchetti2, Soraya Maret2, Kourosh Massiha2, Virginie Mathey-Doret2, Tom Membrez2, Natacha Michel2, Emmanuelle Mohbat2, Hugo-Ken Oulevey2, Irene Saksaralidze2, Milena Stimec2, Natacha Vincent2, Kor-Gaël Toruslu2, Nawel Tounsi2, Vincent2, Manon Will2, Alenka Zeballos Valle2, François Chappuis1, 2, Delphine Courvoisier1, Laurent Gétaz1, 2, Mayssam Nehme1, Febronio Pardo22, Guillelmette Violot23, Sylvie Welker1, Alison Chiovini1, Odile Desvachez16, Benjamin Emery2, Acem Gonul1, Samia Hurst2, Gaëlle Lamour21, Yasmina Malim1, Philippe Matute1, Jean-Michel Maugy22, Aleksandra Mitrovic1, Didier Pittet1, 15, Klara M. Posfay-Barbe3, 10, Jean-François Pradeau22, Christiane Rochia Fine1, Lilas Salzmann-Bellard1, Mélane Seixas Miranda15, Michel Tacchino22, Carol Theurillat1, Sophie Theurillat21, Mélissa Tomasini1, Didier Tron1, 11, Zoé Waldman2

1. Division of Primary Care, Geneva University Hospitals, Geneva, Switzerland
2. Faculty of Medicine, University of Geneva, Geneva, Switzerland
3. University Centre for General Medicine and Public Health, University of Lausanne, Lausanne, Switzerland
4. Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland
5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
6. Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
7. Institut Ethique, Histoire, Humanités, University of Geneva, Geneva, Switzerland
8. Faculty of BioMedicine, Università della Svizzera italiana, Lugano, Switzerland
9. Geneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
10. Division of General Pediatrics, Geneva University Hospitals, Geneva, Switzerland
11. School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
12. Infection Prevention and Control program and World Health Organization
WHO Collaborating Centre on Patient Safety, Geneva University Hospitals, Geneva, Switzerland
13. Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
14. Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland
15. Division of Diagnostics, Geneva University Hospitals, Geneva, Switzerland
16. Division of Women, Children and Adolescents, Geneva University Hospitals, Geneva, Switzerland
17. Campus Biotech, Geneva, Switzerland
18. Education Structure, University of Geneva, Geneva, Switzerland
19. Institute of Social and Preventive Medicine, Bern, Switzerland
20. Deutsches Primatenzentrum (DPZ), Göttingen University, Göttingen, Germany
21. Human Resources Department, Geneva University Hospitals, Geneva, Switzerland
22. Information Systems Division, Geneva University Hospitals, Geneva, Switzerland
23. Division of Communication, Geneva University Hospitals, Geneva, Switzerland